Tranexamic Acid in Adolescents With Heavy Menstrual Bleeding
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01846507|
Recruitment Status : Active, not recruiting
First Posted : May 3, 2013
Last Update Posted : February 13, 2017
This is a study to learn more about a drug called Tranexamic acid (TA), otherwise known as Lysteda, and whether or not this drug can decrease menstrual blood loss in young women and lead to an increase in the quality of life.
Menorrhagia in young women with bleeding disorders is typically treated with a combination of treatments including hormonal contraceptives. However, there are barriers to hormonal contraception use in younger adolescents.
Tranexamic acid is taken orally during the first 5 days of menstrual bleeding.
The purposes of this study include:
To test the safety and efficacy of Lysteda in adolescent females. To learn how well Lysteda works in decreasing menstrual blood loss. To see if parents and children participating in this study think the drug is improving their quality of life.
Lysteda has been approved by the Food and Drug Administration for use in patients > than 18 years of age but not for younger patients.
|Condition or disease||Intervention/treatment||Phase|
|Heavy Menstrual Bleeding||Drug: Tranexamic Acid||Phase 4|
This is a multi-center (5 sites) open-label, single-arm, efficacy study of Lysteda in the treatment of adolescent females (10-19 years of age) with heavy menstrual bleeding (HMB). Each subject will receive oral Lysteda 1.3 grams three times daily during the first five days of menses. Subjects will be monitored over the course of four menstrual cycles (1 pre-treatment cycle and 3 treatment cycles). During all cycles, assessments of menstrual bleeding will be performed using the Menorrhagia Impact Questionnaire (MIQ) and Pictorial Blood Assessment Chart (PBAC).
The study will begin as a currently funded pilot study to assess the efficacy of Lysteda in 32 patients followed to study completion.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||30 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Tranexamic Acid in Adolescents With Heavy Menstrual Bleeding|
|Study Start Date :||April 2013|
|Estimated Primary Completion Date :||May 2017|
|Estimated Study Completion Date :||May 2017|
|Experimental: tranexamic acid||
Drug: Tranexamic Acid
Subjects will be instructed to take 2 tablets (1300) mg of Lysteda three times daily (3900 mg/daily) for five days during monthly menstruation.
Other Name: Lysteda
- Quality of Life [ Time Frame: 6 months ]Improvement in health-related quality of life as defined by a ≥1 point increase in the total Menorrhagia Impact Questionnaire (MIQ) score.
- Menstrual blood loss, change in hemoglobin, and ferritin concentrations. [ Time Frame: 6 months ]1) Change in menstrual blood loss as measured by Pictorial Blood Assessment Chart (PBAC) scores, 2) change in hemoglobin, and 3) change in ferritin concentrations.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01846507
|United States, Indiana|
|Riley Hospital for Children at IU Health|
|Indianapolis, Indiana, United States, 46202|
|United States, Missouri|
|Children's Mercy Hospital|
|Kansas City, Missouri, United States, 64108|
|United States, Ohio|
|Akron Children's Hospital|
|Akron, Ohio, United States, 44302|
|Rainbow Babies & Children's Hospital|
|Cleveland, Ohio, United States, 44106|
|Nationwide Children's Hospital|
|Columbus, Ohio, United States, 43205|
|Principal Investigator:||Sarah O'Brien, MD, MSc||Nationwide Children's Hospital|